George Zavoico

Reni Benjamin

Thomas Yip

- Oncotelic Therapeutics (OTLC) summarized **two years of significant clinical progress and regulatory validation** across its late-stage pipeline, as of September 12, 2025.  **[908259_db4bb368d19e4a89b57dcd93f215d2e8_0]** 
- Key pipeline advancements include **OT-101 in Phase 3 for pancreatic cancer**, OXi4503 in Phase 2 for AML/MDS and advancing toward Phase 3 design, and AL-101 in Phase 2 for Parkinson's disease and sexual dysfunctions.  **[908259_db4bb368d19e4a89b57dcd93f215d2e8_0]** 
- The company is also advancing **pediatric rare disease programs** with potential for Priority Review Vouchers and a nanomedicine pipeline utilizing the 505(b)(2) pathway.  **[908259_db4bb368d19e4a89b57dcd93f215d2e8_0]** 
- Oncotelic Therapeutics holds a **45% ownership stake in GMP Bio**, a joint venture led by its CEO, Dr. Vuong Trieu, which expands its portfolio in oncology and rare diseases.  **[908259_db4bb368d19e4a89b57dcd93f215d2e8_1]**